UniQuest partners with CSL to develop potential new therapy

13 Jul 2021

A potential therapy developed at The University of Queensland may one day save lives by helping patients recover faster from severe trauma, extensive burns and major surgery.

UniQuest, UQ’s technology transfer company, has partnered with global biotechnology company CSL to accelerate the development of a potential treatment for the repair of blood vessels damaged by inflammation.

The technology was refined by UQ Faculty of Medicine lead researcher Associate Professor Mark Coulthard, a paediatric intensivist at Queensland Children’s Hospital and Professor Trent Woodruff and Dr Nemat Khan at UQ’s School of Biomedical Sciences, and will advance to pre-clinical studies with $500,000 from the CSL Research Acceleration Initiative.

Read full story on UQ News

CSL operates in 35+ countries worldwide.